StockNews.com Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

Equities researchers at StockNews.com initiated coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note issued on Tuesday. The firm set a “hold” rating on the stock.

NovaBay Pharmaceuticals Trading Down 4.3 %

Shares of NovaBay Pharmaceuticals stock opened at $0.62 on Tuesday. The firm’s 50 day moving average is $0.65 and its 200 day moving average is $0.63. The firm has a market capitalization of $3.61 million, a PE ratio of -0.01 and a beta of 0.73. NovaBay Pharmaceuticals has a 1 year low of $0.36 and a 1 year high of $9.08.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.